139 related articles for article (PubMed ID: 21221201)
1. Association of Polymorphisms in the Prostate-Specific Antigen (PSA) Gene Promoter with Serum PSA Level and PSA Changes after Dutasteride Treatment in Korean Men with Benign Prostatic Hypertrophy.
Park SW; Kim CS; Lee G
Korean J Urol; 2010 Dec; 51(12):824-30. PubMed ID: 21221201
[TBL] [Abstract][Full Text] [Related]
2. Association between genetic polymorphisms in the prostate-specific antigen gene promoter and serum prostate-specific antigen levels.
Cramer SD; Chang BL; Rao A; Hawkins GA; Zheng SL; Wade WN; Cooke RT; Thomas LN; Bleecker ER; Catalona WJ; Sterling DA; Meyers DA; Ohar J; Xu J
J Natl Cancer Inst; 2003 Jul; 95(14):1044-53. PubMed ID: 12865450
[TBL] [Abstract][Full Text] [Related]
3. Influence of baseline variables on changes in International Prostate Symptom Score after combined therapy with dutasteride plus tamsulosin or either monotherapy in patients with benign prostatic hyperplasia and lower urinary tract symptoms: 4-year results of the CombAT study.
Roehrborn CG; Barkin J; Tubaro A; Emberton M; Wilson TH; Brotherton BJ; Castro R
BJU Int; 2014 Apr; 113(4):623-35. PubMed ID: 24127818
[TBL] [Abstract][Full Text] [Related]
4. Contribution of genetic variation rs266882 to prostate-specific antigen levels in healthy controls with serum PSA below 2.0 ng/ml.
Song J; Park H; Lee G
Biochem Genet; 2013 Apr; 51(3-4):264-74. PubMed ID: 23315126
[TBL] [Abstract][Full Text] [Related]
5. [Specific antigen prostatic changes during treatment with finasteride or dutasteride for benign prostatic hyperplasia].
Arena F
Minerva Urol Nefrol; 2013 Sep; 65(3):211-6. PubMed ID: 23872632
[TBL] [Abstract][Full Text] [Related]
6. Relationship among serum testosterone, sexual function, and response to treatment in men receiving dutasteride for benign prostatic hyperplasia.
Marberger M; Roehrborn CG; Marks LS; Wilson T; Rittmaster RS
J Clin Endocrinol Metab; 2006 Apr; 91(4):1323-8. PubMed ID: 16434455
[TBL] [Abstract][Full Text] [Related]
7. The different reduction rate of prostate-specific antigen in dutasteride and finasteride.
Choi YH; Cho SY; Cho IR
Korean J Urol; 2010 Oct; 51(10):704-8. PubMed ID: 21031091
[TBL] [Abstract][Full Text] [Related]
8. Relationship between serum prostate-specific antigen and prostate volume in Korean men with benign prostatic hyperplasia: a multicentre study.
Chung BH; Hong SJ; Cho JS; Seong DH
BJU Int; 2006 Apr; 97(4):742-6. PubMed ID: 16536765
[TBL] [Abstract][Full Text] [Related]
9. Improvements in benign prostatic hyperplasia-specific quality of life with dutasteride, the novel dual 5alpha-reductase inhibitor.
O'Leary MP; Roehrborn C; Andriole G; Nickel C; Boyle P; Höfner K
BJU Int; 2003 Aug; 92(3):262-6. PubMed ID: 12887480
[TBL] [Abstract][Full Text] [Related]
10. Clinical usefulness of serum prostate specific antigen for the detection of prostate cancer is preserved in men receiving the dual 5alpha-reductase inhibitor dutasteride.
Andriole GL; Marberger M; Roehrborn CG
J Urol; 2006 May; 175(5):1657-62. PubMed ID: 16600723
[TBL] [Abstract][Full Text] [Related]
11. Clinical outcomes after combined therapy with dutasteride plus tamsulosin or either monotherapy in men with benign prostatic hyperplasia (BPH) by baseline characteristics: 4-year results from the randomized, double-blind Combination of Avodart and Tamsulosin (CombAT) trial.
Roehrborn CG; Barkin J; Siami P; Tubaro A; Wilson TH; Morrill BB; Gagnier RP
BJU Int; 2011 Mar; 107(6):946-54. PubMed ID: 21332630
[TBL] [Abstract][Full Text] [Related]
12. The influence of baseline parameters on changes in international prostate symptom score with dutasteride, tamsulosin, and combination therapy among men with symptomatic benign prostatic hyperplasia and an enlarged prostate: 2-year data from the CombAT study.
Roehrborn CG; Siami P; Barkin J; Damião R; Becher E; Miñana B; Mirone V; Castro R; Wilson T; Montorsi F;
Eur Urol; 2009 Feb; 55(2):461-71. PubMed ID: 19013011
[TBL] [Abstract][Full Text] [Related]
13. Association of IL10, IL10RA, and IL10RB polymorphisms with benign prostate hyperplasia in Korean population.
Yoo KH; Kim SK; Chung JH; Chang SG
J Korean Med Sci; 2011 May; 26(5):659-64. PubMed ID: 21532858
[TBL] [Abstract][Full Text] [Related]
14. Polymorphisms in prostate-specific antigen (PSA) gene, risk of prostate cancer, and serum PSA levels in Japanese population.
Wang LZ; Sato K; Tsuchiya N; Yu JG; Ohyama C; Satoh S; Habuchi T; Ogawa O; Kato T
Cancer Lett; 2003 Dec; 202(1):53-9. PubMed ID: 14643026
[TBL] [Abstract][Full Text] [Related]
15. SRD5A1 and SRD5A2 are associated with treatment for benign prostatic hyperplasia with the combination of 5α-reductase inhibitors and α-adrenergic receptor antagonists.
Gu X; Na R; Huang T; Wang L; Tao S; Tian L; Chen Z; Jiao Y; Kang J; Zheng S; Xu J; Sun J; Qi J
J Urol; 2013 Aug; 190(2):615-9. PubMed ID: 23499746
[TBL] [Abstract][Full Text] [Related]
16. Serum prostate-specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia.
Roehrborn CG; Boyle P; Gould AL; Waldstreicher J
Urology; 1999 Mar; 53(3):581-9. PubMed ID: 10096388
[TBL] [Abstract][Full Text] [Related]
17. Association Study of Polymorphisms of Epidermal Growth Factor and Epidermal Growth Factor Receptor With Benign Prostatic Hyperplasia in a Korean Population.
Kim SK; Park HK; Choi HS; Yoo KH; Chung JH
Int Neurourol J; 2016 Dec; 20(4):363-370. PubMed ID: 28043105
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of Adding Dutasteride to α-Blocker Therapy Treated Benign Prostatic Hyperplasia Patients with Small Volume Prostate (<30 mL).
Hashimoto M; Shimizu N; Sugimoto K; Hongoh S; Minami T; Nozawa M; Yoshimura K; Hirayama A; Tahara H; Uemura H
Low Urin Tract Symptoms; 2017 Sep; 9(3):157-160. PubMed ID: 26991643
[TBL] [Abstract][Full Text] [Related]
19. 5α-Reductase inhibitor is less effective in men with small prostate volume and low serum prostatic specific antigen level.
Lin VC; Liao CH; Wang CC; Kuo HC
J Formos Med Assoc; 2015 Sep; 114(9):865-71. PubMed ID: 24064231
[TBL] [Abstract][Full Text] [Related]
20. Genetic variations in VDR associated with prostate cancer risk and progression in a Korean population.
Oh JJ; Byun SS; Lee SE; Hong SK; Jeong CW; Kim D; Kim HJ; Myung SC
Gene; 2014 Jan; 533(1):86-93. PubMed ID: 24120391
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
